{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"74","upperLimit":"83","value":"79"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"336"}],"units":"Participants"}],"description":"Disease progression is defined using the 2007 revised Cheson et al. criteria that is at least 50% increase in sum of the product of the diameters (SPD) of target measurable nodal lesions over the smallest sum observed, or \\>= 50% increase in greatest transverse diameter (GTD) of any nodal \\> 1 cm in shortest axis, or \\>= 50% increase in the SPD of other target measurable lesions over the smallest sum observed, any new bone marrow involvement, any new lesion, lymph node with long axis is \\> 1.5 cm or if both long and short axes are \\> 1 cm, PET positive if patients with no pretreatment PET scan or when PET scan was positive before therapy. Progression-free survival is measured from date of registration to date of first observation of progressive disease, or death due to any cause. Patients last known to be alive and progression-free are censored at date of last contact.","dispersionType":"95% Confidence Interval","groups":[{"description":"HIV-negative patients treated with 2 cycles of ABVD followed by response-adapted therapy. Initial ABVD: Doxorubicin 25 mg/m\\^2 IV, Bleomycin 10u/m\\^2 IV, Vinblastine 6mg/m\\^2 IV, Dacarbazine 375 mg/m\\^2 IV Days 1,15 Q 28 Days x 2 cycles. Interim PET-negative patients continue with 4 cycles of ABVD: Doxorubicin 25 mg/m\\^2 IV, Bleomycin 10u/m\\^2 IV, Vinblastine 6mg/m\\^2 IV, Dacarbazine 375 mg/m\\^2 IV Days 1,15 Q 28 Days x 4 cycles. Interim PET-positive patients receive 6 cycles of escalated BEACOPP: Etoposide 200 mg/m\\^2 IV Days 1, 2, 3, Doxorubicin 35 mg/m\\^2 IV Day 1, Cyclophosphamide 1,250 mg/m\\^2 IV Day 1, Procarbzine 100 mg/m\\^2 PO Days 1-7, Prednisone 40 mg/m\\^2 PO Days 1-14, Bleomycin 10u/m\\^2 IV Day 8, Vincristine 1.4 mg/m\\^2 IV Day 8, G-CSF 5mcg/kg/day SQ Days 8-14, Q 21 Days x 6 cycles.","id":"OG000","title":"HIV-negative: 2 Cycles of ABVD Followed by PET-directed Therap"}],"paramType":"NUMBER","populationDescription":"Eligible and evaluable HIV-negative patients who started initial ABVD were included in the analysis regardless the response-adapted therapy after 2 initial cycles of ABVD was administered.","reportingStatus":"POSTED","timeFrame":"2 years","title":"Percentage of HIV-negative Patients With 2-year Progression-free Survival (PFS) Treated With 2 Initial Cycles of Adriamycin, Bleomycin, Vnblastine, and Dacarbazine (ABVD) Followed by Response-adapted Therapy Based on Interim FDG-PET Imaging.","type":"PRIMARY","unitOfMeasure":"percentage of participants"}